Chromium bond detection in isolated erythrocytes: a new principle of biological monitoring of exposure to hexavalent chromium

  • J. Lewalter
  • U. Korallus
  • C. Harzdorf
  • H. Weidemann
Original Papers


Internal stress to chromium is only relevant in occupational medicine if it is due to the handling of hexavalent chromium. Cr(VI) ions, after uptake by inhalation or percutaneously are carried in the blood plasma and penetrate—depending on the concentration—into the erythrocytes. Due to the intracellular reduction to Cr(III) and the concurrent intracellular protein binding, the erythrocytes represent an easily accessible target organ for quantitative chromium determination after occupational exposure to Cr(VI) compounds. The results of an earlier experimental study indicate that human plasma too is capable of spontaneous reduction of Cr(VI) ions of up to 2 ppm to Cr(III). This plasma reduction capacity (PRC) can be increased and accelerated considerably by adding ascorbic acid (AA). These findings were supported in this investigation by proving a decreased binding of Cr(VI) inside the erythrocytes under the effect of AA. This leads to the assumption that only those Cr(VI) concentrations can penetrate the membrane of the erythrocytes and enter the cell which either come into contact with the membrane during the reduction process or exceed this limit concentration of 2 ppm. Only in these two instances can corresponding chromium findings be analyzed in isolated and washed erythrocytes. These results are compared with those obtained by conventional methods, such as Cr determination in the blood and/or urine. Our findings indicate that a single determination of chromium concentration in the erythrocytes will permit the monitoring of critical cases of Cr(VI) exposure. This is a new type of biological monitoring in the sense of a condensed longitudinal study, in order to find out whether threshold concentrations have been respected over a given period.

Key words

Cr(III) compounds Cr(VI) compounds Conjugation of Cr(VI) compounds with erythrocytes Separation of erythrocytes Biological monitoring for Cr(VI) 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aaseth J, Alexander J, Norseth T (1982) Uptake of 51Cr-chromate by human erythrocytes —a role of glutathione. Acta Pharmacol Toxicol 50:310–315Google Scholar
  2. 2.
    Cooper M, Owen CA (1956) Labeling human erythrocytes with radiochromium. J Lab Clin Med 47:65–71Google Scholar
  3. 3.
    Donohue M, Motulsky AG, Giblett ER, Pirzio-Biroli G, Viranuvatti V, Finch CA (1955) The use of 51Cr as a red cell tag. Br J Haematol 1:249Google Scholar
  4. 4.
    Ebaugh FG, Emerson CP, Ross JF (1953) The use of radioactive 51chromium as an erythrocyte tagging agent for the determination of red cell survival in vivo. J Clin Invest 32:1260Google Scholar
  5. 5.
    Emerson CP, Bove JR (1960/1962) Measurements of 51Chromium elution from labelled donor erythrocytes. Proc 8th Cong Int Soc Blood Transf, Tokyo (1960). Karger, Basel, p 241Google Scholar
  6. 6.
    Emrich D (1971) Nuclearmedizin-Funktionsdiagnostik. Thieme, Stuttgart, pp 119–120Google Scholar
  7. 7.
    Gray SJ, Sterling K (1950) Determination of the red cell volume in man by radioactive chromium. J Clin Invest 29:1614Google Scholar
  8. 8.
    Jandl JH, Greenberg MS, Yonemoto RH, Castle WB (1956) Clinical determination of the sites of red cell sequestration in hemolytic anaemias. J Clin Invest 35:842Google Scholar
  9. 9.
    Kleine N, Heimpel H (1965) The early loss of radioactivity in 51Cr survival curves: destruction of cells or loss of the label? Blood 26:819Google Scholar
  10. 10.
    Korallus U, Harzdorf C, Lewalter J (1984) Experimental bases of ascorbic acid therapy of poisoning by hexavalent chromium compounds. Int Arch Occup Environ Health 53:247–256Google Scholar
  11. 11.
    Langård S, Gundersen N, Tsalev DL, Gylseth B (1978) Whole blood chromium level and chromium excretion in rat after zinc-chromate inhalation. Acta Pharmacol Toxicol 42:142–149Google Scholar
  12. 12.
    Leonard A, Lauwerys RR (1980) Carcinogenicity and mutagenicity of chromium. Mutat Res 76:227–239Google Scholar
  13. 13.
    Malcolm D, Ramey HM, Jacobs AS (1963) Association of radioactives chromium with various components of hemoglobin. Blood 21:8Google Scholar
  14. 14.
    Mollison PL, Veall N (1955) The use of the isotope 51Cr as a label for red cells. Br J Haematol 1:64Google Scholar
  15. 15.
    Prins HK (1962) The bindings of 51Cr by human erythrocytes. Vox Sang 7:370Google Scholar
  16. 16.
    Pruszkowska E, Càrnrick GR, Slavin W (1983) Blood lead determination with the platform furnace technique. At Spectrosc 4:59Google Scholar
  17. 17.
    Samitz MH, Shrager J, Katz S (1962) Studies on the prevention of injurious effects of chromates in industry. Ind Med Surg 31:427–432Google Scholar
  18. 18.
    Stoeppler M, Brandt K, Rains TC (1978) Rapid method for the automated determination of lead in whole blood by electrothermal AAS. Analyst 103:7Google Scholar
  19. 19.
    Weber H (1983) Long-term study of the distribution of soluble chromate-51 in the rat after a single intratracheal administration. J Toxicol Environ Health 11:749–764Google Scholar
  20. 20.
    Welinder H, Littorin M, Gullberg B, Skerfving S (1983) Elimination of chromium in urine after stainless steel welding. Scand J Work Environ Health 9:397–403Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • J. Lewalter
    • 1
  • U. Korallus
    • 1
  • C. Harzdorf
    • 2
  • H. Weidemann
    • 2
  1. 1.WV-LE Medical DepartmentGermany
  2. 2.GB AC-Research, Bayer AGLeverkusenGermany

Personalised recommendations